Compare XRAY & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRAY | KLRA |
|---|---|---|
| Founded | 1899 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2009 | 2026 |
| Metric | XRAY | KLRA |
|---|---|---|
| Price | $11.36 | $16.32 |
| Analyst Decision | Hold | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $14.58 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 645.7K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | ★ 5.58% | N/A |
| EPS Growth | ★ 33.04 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.06 | N/A |
| P/E Ratio | $81.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.41 | $15.15 |
| 52 Week High | $14.73 | $23.82 |
| Indicator | XRAY | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 39.00 |
| Support Level | $10.84 | N/A |
| Resistance Level | $11.48 | $19.02 |
| Average True Range (ATR) | 0.43 | 1.28 |
| MACD | 0.04 | -0.15 |
| Stochastic Oscillator | 65.33 | 16.77 |
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.